title: Rationale for treating cancer with somatostatin analogs.
authors.affiliation: Department of Endocrinology and Metabolism, University of Genoa, Genoa, Italy. minuto@unige.it
authors.forename: F
authors.initials: F
authors.lastname: Minuto
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: M
authors.initials: M
authors.lastname: Arvigo
authors.forename: A
authors.initials: A
authors.lastname: Barreca
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D006801:Humans; D008938:Mitosis / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017481:Receptors, Somatostatin / Q000145:classification / Q000187:drug effects / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D013004:Somatostatin